Free tool
FAERS Monitor: Venclexta
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208573 or its brand name (Venclexta, Venetoclax). Reports on generic versions are filed under their own applications.
Reports
62,878
Serious
56,926
91% of reports
Hospitalization
24,262
Death reported
17,658
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death10,347
- off label use7,028
- neutropenia3,635
- febrile neutropenia3,178
- myelosuppression3,045
- platelet count decreased2,936
- pyrexia2,849
- pneumonia2,733
- fatigue2,723
- diarrhoea2,438
- white blood cell count decreased2,384
- thrombocytopenia2,281
- nausea2,182
- anaemia2,090
- infection2,017
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2014 | 4 |
| 2015 | 23 |
| 2016 | 691 |
| 2017 | 1,800 |
| 2018 | 3,586 |
| 2019 | 5,067 |
| 2020 | 5,631 |
| 2021 | 6,270 |
| 2022 | 11,152 |
| 2023 | 8,891 |
| 2024 | 7,506 |
| 2025 | 7,297 |
| 2026 | 4,960 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,991,281 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| myelosuppressionSignal | 3,045 | 30.8 | 29.7 | 80,479 |
| febrile neutropeniaSignal | 3,178 | 16.8 | 16.2 | 45,033 |
| platelet count decreasedSignal | 2,936 | 9.4 | 9.1 | 21,666 |
| neutropeniaSignal | 3,635 | 9.2 | 8.9 | 25,879 |
| white blood cell count decreasedSignal | 2,384 | 7.5 | 7.2 | 13,196 |
| thrombocytopeniaSignal | 2,281 | 6.9 | 6.7 | 11,425 |
| infectionSignal | 2,017 | 4.7 | 4.5 | 5,855 |
| deathSignal | 10,347 | 4.1 | 4.0 | 24,522 |
| anaemiaSignal | 2,090 | 3.7 | 3.5 | 4,098 |
| pneumoniaSignal | 2,733 | 2.8 | 2.7 | 3,277 |
| pyrexiaSignal | 2,849 | 2.8 | 2.7 | 3,244 |
| off label useSignal | 7,028 | 2.7 | 2.6 | 7,775 |
| diarrhoea | 2,438 | 1.3 | 1.2 | 138 |
| fatigue | 2,723 | 1.2 | 1.1 | 70 |
| nausea | 2,182 | 0.9 | 0.9 | 15 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.